A phase II trial reported promising results for a combination of quizartinib and omacetaxine mepesuccinate in a high-risk AML setting. The study, published in Nature Communications in 2026, examined whether pairing the investigational approach could improve outcomes in aggressive disease biology. The report emphasizes mechanistic synergy between the agents and frames the data as supportive for further development in AML subgroups that have limited durable responses. As with many phase II signals, the key next step is whether efficacy holds in larger randomized studies and across multiple centers. Clinically, the combination approach adds to the growing push for regimen-level personalization in AML based on subtype behavior and resistance patterns.